[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:amyloid-beta-peptide":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Amyloid beta peptide",10,8,[8,16,23,30,36,43,49,55,61,68],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06647498","A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation",[12],"Phase 2\u002FPhase 3","RECRUITING","2026-08-26T02:15:48.613507Z","2026-07-30T01:46:14.434425Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07218081","A Trial to Test Intermittent Deep Brain Stimulation of Nucleus Basalis of Meynert to Treat Alzheimers.",[20],"Phase 1","2026-08-26T02:16:38.053590Z","2026-04-29T02:57:57.123929Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT07589595","A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)",[27],"Phase 2","2026-08-26T02:18:06.247899Z","2026-05-29T15:36:40.200991Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT06514001","A Study of AMDX-2011P in Participants With Alzheimer's Disease",[27],"2026-08-26T02:15:44.309045Z","2026-05-05T02:43:28.835331Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":41,"content_modified":42},"NCT05395624","Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers",[40],"Phase 1\u002FPhase 2","2026-08-26T02:15:34.659160Z","2026-05-05T02:43:28.209644Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT06566170","A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease",[],"2026-08-26T02:16:00.194860Z","2026-05-13T02:55:06.510944Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT06058234","Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study",[],"2026-08-26T02:17:54.420226Z","2026-05-13T02:55:06.404227Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT04902703","Phase II Trial to Evaluate Safety and Efficacy of GM-CSF\u002FSargramostim in Alzheimer's Disease",[27],"2026-08-26T02:15:31.806698Z","2026-05-05T02:43:28.531913Z",{"nct_id":62,"title":63,"phases":64,"status":65,"updated_at":66,"content_modified":67},"NCT07511179","Personalized Closed-Loop Brain Stimulation for Patients With Primary Progressive Aphasia",[],"NOT_YET_RECRUITING","2026-08-26T02:18:02.701182Z","2026-05-05T02:43:27.660701Z",{"nct_id":69,"title":70,"phases":71,"status":72,"updated_at":73,"content_modified":74},"NCT05464368","R21 Roche: 3-Way Tau Tracers in AD",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T03:32:10.191597Z","2026-05-05T02:43:26.951822Z"]